Markers predicting clinical benefit in breast cancer from microtubule-targeting agents.

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

Volumn 18 Suppl 12, Issue , 2007, Pages

  Pusztai, L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; TAXOID; TUMOR MARKER;

BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; METABOLISM; MICROTUBULE; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICROTUBULES; P-GLYCOPROTEIN; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 38749089490     PISSN: None     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm534     Document Type: Review

References (51)